Forum Topic News
  • Conversation: EU approves first-line use of AZ’ Tagrisso in lung cancer

    • June 11, 2018 12:53 PM BST
    • EU approves first-line use of AZ’ Tagrisso in lung cancer

      AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
      The decision, which significantly expands the drug’s reach in the EU, was based on clinical data from the Phase III FLAURA trial, showing that progression free survival in patients taking Tagrisso (osimertinib) was 18.9 months compared to 10.2 months for those receiving the standard of care, while the objective response rate was 80 percent versus 76 percent, respectively.
      A further recent analysis of FLAURA results - presented at the European Lung Cancer Conference (ELCC) in Geneva - also showed that the drug’s PFS benefit over EGFR tyrosine kinase inhibitors (TKIs) was sustained throughout post-progression outcomes.
      Read more: http://www.pharmatimes.com/news/eu_approves_first-line_use_of_az_tagrisso_in_lung_cancer_1239303

Add Reputation

Do you want to add reputation for this member by this post?

or cancel